Literature DB >> 12507625

Changing times for the management of diabetic retinopathy.

Donald S Fong1.   

Abstract

Laser photocoagulation has led a revolution in the management of diabetic retinopathy. Scatter photocoagulation and focal photocoagulation has been shown to be effective in reducing vision loss. Just as dramatic as laser photocoagulation, medical treatment has led another revolution in the treatment of diabetic retinopathy. Good glycemic, blood pressure, and lipid control have contributed to further reduce vision loss and laser photocoagulation. In the very near future, there will be significant advances in pharmacologic treatment of diabetic retinopathy. Treatment with antioxidants, agents inhibiting hyperglycemia-induced protein kinase activity, and other agents will likely prevent the development/progression of retinopathy. Because pharmacologic agents are aimed at the prevention of retinopathy, patients with retinopathy will need to be examined earlier to diagnose retinopathy at earlier stages. To maximize the opportunity for earlier diagnosis, ophthalmologist may need to adopt screening strategies to identify patients most likely to benefit from these new treatments.

Entities:  

Mesh:

Year:  2002        PMID: 12507625     DOI: 10.1016/s0039-6257(02)00389-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  2 in total

1.  Laser photocoagulation enhances adeno-associated viral vector transduction of mouse retina.

Authors:  Si Hyung Lee; Peter Colosi; Heuiran Lee; Young-Hoon Ohn; Sung-Woon Kim; Hyung Woo Kwak; Tae Kwann Park
Journal:  Hum Gene Ther Methods       Date:  2013-12-28       Impact factor: 2.396

2.  The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.

Authors:  Gabriele E Lang; Sandra Liakopoulos; Jessica Vögeler; Claudia Weiß; Georg Spital; Maria-Andreea Gamulescu; Chris Lohmann; Peter Wiedemann
Journal:  Acta Ophthalmol       Date:  2017-11-01       Impact factor: 3.761

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.